Defining the clinical utility of gene expression assays in breast cancer: The intersection of science and art in clinical decision making

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1625-1627

  Sparano, Joseph A ^a   Solin, Lawrence J ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CLINICAL FEATURE; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DECISION MAKING; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT INDICATION; BREAST TUMOR; DECISION MAKING; DISEASE COURSE; FEMALE; GENETICS; METASTASIS; NOTE; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; DECISION MAKING; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 77950500673     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2882     Document Type: Editorial

References (34)

1. Saunders J: The practice of clinical medicine as an art and as a science. Med Humanit 26:18-22, 2000
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Piquette-Miller M, Grant DM: The art and science of personalized medicine. Clin Pharmacol Ther 81:311-315, 2007 (Pubitemid 46364497)
4. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
5. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
6. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
7. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004 (Pubitemid 38748922)
8. Ma XJ, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608, 2008
9. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006 (Pubitemid 44200649)
10. Lo SS, Murphy PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
11. Mamounas EP, Tang G, Fisher B, et al: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor - positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677-1683, 2010
12. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008 (Pubitemid 351264384)
13. Yang HC, Thornton LM, Shapiro CL, et al: Surviving recurrence: Psychological and quality-of-life recovery. Cancer 112:1178-1187, 2008 (Pubitemid 351304605)
14. Andersen BL, Shapiro CL, Farrar WB, et al: Psychological responses to cancer recurrence. Cancer 104:1540-1547, 2005
15. Fisher B, Anderson S, Fisher ER, et al: Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338:327-331, 1991
16. Wapnir IL, Anderson SJ, Mamounas EP, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028-2037, 2006 (Pubitemid 46622111)
17. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005 (Pubitemid 41797643)
18. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
19. Anderson SJ, Wapnir I, Dignam JJ, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466-2473, 2009
20. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997 (Pubitemid 27508191)
21. Chagpar A, Kuerer HM, Hunt KK, et al: Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: Implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys 57:128-135, 2003 (Pubitemid 36959748)
22. Cefaro GA, Genovesi D, Marchese R, et al: Predictors of local recurrence after conservative surgery and whole-breast irradiation. Breast Cancer Res Treat 98:329-335, 2006 (Pubitemid 44195603)
23. Horst KC, Smitt MC, Goffinet DR, et al: Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer 5:425-438, 2005
24. Nuyten DS, Kreike B, Hart AA, et al: Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62, 2006
25. Carlson RW, Brown E, Burstein HJ, et al: NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4:S1-S26, 2006
26. Simes RJ, Coates AS: Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? J Natl Cancer Inst Monogr 30:146-152, 2001
27. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
28. Mongan JJ, Ferris TG, Lee TH: Options for slowing the growth of health care costs. N Engl J Med 358:1509-1514, 2008
29. Iglehart JK: Prioritizing comparative-effectiveness research: IOM recommendations. N Engl J Med 361:325-328, 2009
30. Asad J, Jacobson AF, Estabrook A, et al: Does Oncotype DX recurrence score effect management of patients with early stage breast cancer. Am J Surg 196:527-529, 2008
31. Oratz R, Paul D, Cohn AL, Sedlacek SM: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. Journal of Oncology Practice 3:182-186, 2007 (Pubitemid 351593669)
32. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
33. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
34. Paik S, Tang G, Fumagalli D: An ideal prognostic test for estrogen receptor-positive breast cancer? J Clin Oncol 26:4058-4059, 2008